NBIX - Neurocrine Biosciences Inc. (NBIX) Q1 2024 Earnings Call Transcript
2024-05-01 12:38:10 ET
Neurocrine Biosciences, Inc. (NBIX)
Q1 2024 Earnings Conference Call
May 1, 2024 08:00 AM ET
Company Participants
Todd Tushla - VP, IR
Kevin Gorman - CEO
Matt Abernethy - CFO
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Kyle Gano - Chief Business Development & Strategy Officer
Conference Call Participants
Tazeen Ahmad - Bank of America
Phil Nadeau - TD Cowen
Paul Matteis - Stifel
Chris Shibutani - Goldman Sachs
Akash Tewari - Jefferies
Jay Olson - Oppenheimer
Mohit Bansal - Wells Fargo
Brian Skorney - Baird
Brian Abrahams - RBC Capital Markets
Carter Gould - Barclays
Anupam Rama - JPMorgan
Marc Goodman - Leerink
Myles Minter - William Blair
Jeff Hung - Morgan Stanley
Laura Chico - Wedbush Securities
Danielle Brill Bongero - Raymond James
Yatin Suneja - Guggenheim
Sumant Kulkarni - Canaccord
Evan Seigerman - BMO
David Hoang - Citigroup
Ami Fadia - Needham
David Amsellem - Piper Sandler
Presentation
Operator
Good day everyone and welcome to Neurocrine Biosciences' reports First Quarter Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions]
It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Good morning everyone, and welcome to Neurocrine Biosciences' first quarter 2024 earnings call. With me are Kevin Gorman, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eiry Roberts, Chief Medical Officer; Eric Benevich, Chief Commercial Officer; and Kyle Gano, Chief Business Development and Strategy Officer. We are also joined today by Dr. Jaz Singh, Neurocrine's Vice President of Psychiatry Clinical Development, which includes serving as the program lead for NBI-845, our AMPA potentiator, which recently read out positive Phase 2 top-line results in adults with major depressive disorder.
Jaz has been at Neurocrine since 2020. Prior to joining Neurocrine, Jaz spent 14 years at Johnson & Johnson where among other things he led the clinical efforts for the esketamine program through approval. I'm sure you'll have a few questions not only for Jaz but for also Eiry and Kyle today on the 845 program.
With introductions complete, I'll remind you that we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings.
At this point, I'll turn the call over to Kevin.
Kevin Gorman
Thank you, Todd. Good morning, everyone. We've had a remarkable week and it's only Wednesday morning. We submitted two NDAs on [Kinesapant] and received an FDA approval for a new offering of Ingrezza. I'm thinking about giving the company the rest of the week off. Neurocrine has never had the opportunity to positively impact so many lives as it has today. As you will hear in greater detail from Matt, Eric, Eiry, we are making progress in every aspect of our business focused on bringing life-changing medicines forward. We have never treated as many TD and HC patients as we are treating today. We have never had a deep, a mid and late stage clinical pipeline and now we have a good line of sight into a number of potentially new medicines coming into the clinic from our research group in the next two years, several of them with the promise of disease modification....
Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript